Frequency of and reasons behind non-listing in adult patients referred for liver transplantation: Results from a retrospective study

Table 2 Clinical features of patients

	All patients (n = 314)	Listed (n = 145)	Non-listed (n = 169)	P value
Age (yr)	54.6 ± 11.5	54.4 ± 10.1	54.7 ± 12.6	NS
Male sex	236 (75.1%)	118 (81.4%)	118 (69.8%)	0.018
Alcohol	130 (41.4%)	61 (42.1%)	69 (40.8%)	NS
HCC	112 (35.7%)	63 (43.4%)	49 (29%)	0.008
Active HBV	35 (11.1%)	19 (13.1%)	16 (9.5%)	NS
Past HBV	32 (10.2%)	22 (15.2%)	10 (5.9%)	0.007
HCV	70 (22.3%)	36 (24.8%)	34 (20.1%)	NS
PBC/PSC	23 (7.3%)	15 (10.3%)	8 (4.7%)	NS
Autoimmune	9 (2.9%)	3 (2.1%)	6 (3.6%)	NS
Non-Alcoholic Steatohepatitis	43 (13.7%)	25 (17.2%)	18 (10.6%)	NS
Other indications1	27 (8.6%)	14 (9.6%)	13 (7.7%)	NS
Confirmed or suspected ALF2	34 (10.8%)	8 (5.5%)	26 (15.3%)	0.011
Portal vein thrombosis	52 (16.6%)	28 (19.3%)	24 (14.2%)	NS
TIPS	20 (6.4%)	14 (9.7%)	6 (3.6%)	0.027
Referred from another hospital	102 (32.5%)	33 (22.8%)	69 (40.8%)	0.001

¹Include 6 hepatitis D virus coinfection, 5 polycystic liver disease, 3 re-transplantation, 3 iron overload, 2 secondary biliary cirrhosis, 2 Budd-Chiari Syndrome, 2 Alagille Syndrome, 1 Caroli Syndrome, 1 Wilson disease, 1 drug-induced liver disease, 1 portal hypertensive biliopathy.

²Include: 10 drug-related, 6 indeterminate, 5 hepatitis B virus, 4 hepatitis A virus, 2 hepatitis E virus, 2 iatrogenic, 1 autoimmune, 1 malignant infiltration, 1 amanita phalloides, 1 Hemolysis Elevated Liver enzymes and Low Platelet count syndrome, 1 acute hepatic artery thrombosis.

Data has been presented as the number of patients (%) or mean ± SD. Analysis has been conducted by either a χ² test or independent samples student’s t-test. HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis; ALF: Acute liver failure; TIPS: Transjugular intrahepatic portosystemic shun; NS: Not significant.